ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
0,00%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,89
0,42%
Bitcoin
57 474,07
-1,31%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acasti Pharma Inc (ACST)

  7. Acasti Pharma Inc (ACST) Actualités

ACST Acasti Pharma Inc

2,8501
0,0701 (2,52%)
02 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Acasti Pharma Inc ACST NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0701 2,52% 2,8501 00:13:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,77 2,70 2,93 2,8501 2,78
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
12/2/202414:00EDGAR2Form 8-K - Current report
12/2/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/1/202414:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/1/202413:30EDGAR2Form 8-K - Current report
20/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202313:30EDGAR2Form 8-K - Current report
13/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202322:30EDGAR2Form 8-K - Current report
16/10/202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/10/202322:30EDGAR2Form 8-K - Current report
06/10/202322:30EDGAR2Form S-3 - Registration statement under Securities Act of..
28/9/202301:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202314:10EDGAR2Form 8-K - Current report
05/9/202321:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202323:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
25/8/202322:21EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/8/202322:15EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202313:31EDGAR2Form 8-K - Current report
11/8/202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202323:30EDGAR2Form 8-K - Current report
18/7/202322:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202315:00PRNUSAcasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON..
07/7/202314:30EDGAR2Form 8-K - Current report
07/7/202314:00PRNUSAcasti Pharma Announces 1-for-6 Reverse Stock Split
05/7/202322:00EDGAR2Form 8-K - Current report
05/7/202315:00PRNUSAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase..
23/6/202313:00PRNUSAcasti Pharma Reports Fiscal Year 2023 Operational Results
22/6/202315:00PRNUSAcasti Announces Appointment of New Scientific Advisory..
17/5/202315:00PRNUSAcasti to Participate in the Lytham Partners Spring 2023..
08/5/202313:00PRNUSAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety..

Dernières Valeurs Consultées

NASDAQ
ACST
Acasti Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés